FibroGen, Inc. (0IL8.L)

52.55 -0.14 (-0.26%) As of 2:33PM GMT. Market open.

FibroGen, Inc.

409 Illinois Street
San Francisco, CA 94158
United States
415 978 1200
http://www.fibrogen.com

Sector(s): 
Industry: 
Full-time employees: 531

Key executives

Name	Title	Pay	Exercised	Year born
Mr. James A. Schoeneck	Chairman	751.63k	934.26k	1958
Mr. Pat Cotroneo	Chief Financial Officer	773.57k	3.79M	1964
Dr. K. Peony Yu	Exec. Advisor to Chief Exec. Officer	926.21k	396.02k	1962
Dr. Elias Kouchakji	Sr. VP of Clinical Devel., Drug Safety & Pharmacovigilance	863.19k	471.6k	1956
Ms. Christine L. Chung	Sr. VP of China Operations	701.09k	2.39M	1968
Mr. Enrique A. Conterno	CEO & Director	N/A	N/A	1967
Dr. Barry A. Berkowitz	Founder	N/A	N/A	N/A
Dr. Michael J. Martinelli	Sr. VP of Technical Devel.	N/A	N/A	N/A
Dr. Percy Carter M.B.A., Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Ms. Karen L. Bergman	VP of Investor Relations & Corp. Communications	N/A	N/A	N/A

Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.

Corporate governance

FibroGen, Inc.’s ISS governance QualityScore as of 2 December 2020 is 5. The pillar scores are Audit: 1; Board: 1; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.